# The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

> **NCT06012448** · PHASE4 · COMPLETED · sponsor: **University of Michigan** · enrollment: 10 (actual)

## Conditions studied

- Dermal Hypersensitivity Reaction

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT06012448
- **Lead sponsor:** University of Michigan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-02
- **Primary completion:** 2025-01-07
- **Final completion:** 2025-03-25
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06012448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06012448, "The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06012448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*